CD30 is a member of ihc TNF receptor family that is expressed by a subset of activated T cells (both CD4+ and CD8+) and В cells and is conslilulively present in decidual and exocrine pancreatic cells. In activated T cells, CD30 appears to be preferentially associated with type 2 T helper (TH2) responses, since its expression is at least partly dependent on the presence of IL-4. Moreover, CD30 is present in a variety of tumors, including Hodgkm's lymphoma and поп-Hodgkin's lymphoma, and embryonal carcinomas. A soluble form of CD30 (sCD30) is released in the serum of patients with Hodgkin's lymphoma and other CD30+ tumors, as well as in inflammatory conditions characterized by strong В cell or TH0/TH2 cell activation. The measurement of sCD30 in biological fluids may represent a good marker of disease activity and/or prognosis in such conditions. In vivo CD30-targeting in patients with refractory CD30+ tumors is also being attempted.